{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T04:45:43Z","timestamp":1790829943834,"version":"4.1.0"},"reference-count":38,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Clin Nucl Med"],"published-print":{"date-parts":[[2021,8]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of the Report<\/jats:title>\n            <jats:p>We aimed to evaluate the role of <jats:sup>18<\/jats:sup>F-FDG PET\/CT in predicting patient outcome following chimeric antigen receptor T (CAR T) cells infusion in aggressive B-cell lymphoma.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>\n                                 <jats:sup>18<\/jats:sup>F-FDG PET\/CT data before leukapheresis, before CAR T-cell infusion and 1 month (M1) after CAR T-cell infusion, from 72 patients were retrospectively analyzed. SUVmax, total lesion glycolysis (TLG), metabolic tumor volume (MTV), and parameters describing tumor kinetics were calculated for each <jats:sup>18<\/jats:sup>F-FDG PET\/CT performed. The aim was to evaluate the prognostic value of <jats:sup>18<\/jats:sup>F-FDG PET\/CT metabolic parameters for predicting progression-free survival (PFS) and overall survival (OS) following CAR T-cell therapy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Regarding PFS, \u2206MTV<jats:sup>pre-CAR<\/jats:sup> and \u2206TLG<jats:sup>pre-CAR<\/jats:sup> were found to be more discriminating compared with metabolic parameters at preinfusion. Median PFS in patients with a \u2206MTV<jats:sup>pre-CAR<\/jats:sup> of less than 300% was 6.8 months (95% confidence interval [CI], 2.8 months to not reached) compared with 2.8 months (95% CI, 0.9\u20133.0 months) for those with a value of 300% or greater (<jats:italic toggle=\"yes\">P<\/jats:italic> = 0.004). Likewise, median PFS in patients with \u2206TLG<jats:sup>pre-CAR<\/jats:sup> of less than 420% was 6.8 months (95% CI, 2.8 months to not reached) compared with 2.7 months (95% CI, 1.3\u20133.0 months) for those with a value of 420% or greater (<jats:italic toggle=\"yes\">P<\/jats:italic> = 0.0148). Regarding OS, metabolic parameters at M1 were strongly associated with subsequent outcome. SUVmax at M1 with a cutoff value of 14 was the most predictive parameter in multivariate analysis, outweighing other clinicobiological variables (<jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.0001).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Disease metabolic volume kinetics before infusion of CAR T cells seems to be superior to initial tumor bulk itself for predicting PFS. For OS, SUVmax at M1 might adequately segregate patients with different prognosis.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/rlu.0000000000003756","type":"journal-article","created":{"date-parts":[[2021,6,11]],"date-time":"2021-06-11T21:07:34Z","timestamp":1623445654000},"page":"627-634","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":54,"title":["Prognostic Impact of 18F-FDG PET\/CT in Patients With Aggressive B-Cell Lymphoma Treated With Anti-CD19 Chimeric Antigen Receptor T Cells"],"prefix":"10.1097","volume":"46","author":[{"given":"Pierre","family":"Sesques","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9r\u00e9mie","family":"Tordo","sequence":"additional","affiliation":[{"name":"Nuclear Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuelle","family":"Ferrant","sequence":"additional","affiliation":[{"name":"Department of Haematology, Hospices Civils de Lyon, Lyon Sud Hospital, Pierre-B\u00e9nite"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Violaine","family":"Safar","sequence":"additional","affiliation":[{"name":"Department of Haematology, Hospices Civils de Lyon, Lyon Sud Hospital, Pierre-B\u00e9nite"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florent","family":"Wallet","sequence":"additional","affiliation":[{"name":"Critical Care"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Dhomps","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Brisou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fadhela","family":"Bouafia","sequence":"additional","affiliation":[{"name":"Department of Haematology, Hospices Civils de Lyon, Lyon Sud Hospital, Pierre-B\u00e9nite"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lionel","family":"Karlin","sequence":"additional","affiliation":[{"name":"Claude Bernard Lyon 1 University, Lyon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana","family":"Ghergus","sequence":"additional","affiliation":[{"name":"Claude Bernard Lyon 1 University, Lyon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camille","family":"Golfier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hel\u00e8ne","family":"Lequeu","sequence":"additional","affiliation":[{"name":"Department of Haematology, Hospices Civils de Lyon, Lyon Sud Hospital, Pierre-B\u00e9nite"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Lazareth","sequence":"additional","affiliation":[{"name":"Department of Haematology, Hospices Civils de Lyon, Lyon Sud Hospital, Pierre-B\u00e9nite"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marl\u00e8ne","family":"Vercasson","sequence":"additional","affiliation":[{"name":"Department of Haematology, Hospices Civils de Lyon, Lyon Sud Hospital, Pierre-B\u00e9nite"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carole","family":"Hospital-Gustem","sequence":"additional","affiliation":[{"name":"Department of Haematology, Hospices Civils de Lyon, Lyon Sud Hospital, Pierre-B\u00e9nite"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00e9rane","family":"Schwiertz","sequence":"additional","affiliation":[{"name":"Pharmacy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"Choquet","sequence":"additional","affiliation":[{"name":"Department of Haematology, Hospices Civils de Lyon, Lyon Sud Hospital, Pierre-B\u00e9nite"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Sujobert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvana","family":"Novelli","sequence":"additional","affiliation":[{"name":"INSERM U1052 and CNRS UMR5286, Lyon Cancer Research Center, Lyon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9rie","family":"Mialou","sequence":"additional","affiliation":[{"name":"Department of Biology and Therapy, Etablissement Fran\u00e7ais du Sang Auvergne-Rh\u00f4ne-Alpes"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Hequet","sequence":"additional","affiliation":[{"name":"Department of Biology and Therapy, Etablissement Fran\u00e7ais du Sang Auvergne-Rh\u00f4ne-Alpes"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvain","family":"Carras","sequence":"additional","affiliation":[{"name":"Department of Haematology, Grenoble University Hospital, Grenoble"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludovic","family":"Fouillet","sequence":"additional","affiliation":[{"name":"Department of Haematology, Institut de Canc\u00e9rologie Lucien Neuwirth, Saint-Etienne"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laure","family":"Lebras","sequence":"additional","affiliation":[{"name":"Department of Haematology, Centre L\u00e9on B\u00e9rard, Lyon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yann","family":"Guillermin","sequence":"additional","affiliation":[{"name":"Department of Haematology, Centre L\u00e9on B\u00e9rard, Lyon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9cile","family":"Leyronnas","sequence":"additional","affiliation":[{"name":"Department of Haematology, Groupe Hospitalier Mutualiste, Institut Daniel Hollard, Grenoble"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doriane","family":"Cavalieri","sequence":"additional","affiliation":[{"name":"Department of Haematology, Clermont Ferrand University Hospital, Clermont Ferrand, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Janier","sequence":"additional","affiliation":[{"name":"Nuclear Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herv\u00e9","family":"Ghesqui\u00e8res","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Salles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Bachy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2021,6,11]]},"reference":[{"key":"bib1-20250621","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","year":"2016","journal-title":"Blood"},{"key":"bib2-20250621","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1182\/blood-2014-05-577189","article-title":"Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity","volume":"125","year":"2015","journal-title":"Blood"},{"key":"bib3-20250621","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","article-title":"Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study","volume":"130","year":"2017","journal-title":"Blood"},{"key":"bib4-20250621","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1038\/bmt.2016.213","article-title":"Outcomes of diffuse large B-cell lymphoma patients relapsing after autologous stem cell transplantation: an analysis of patients included in the CORAL study","volume":"52","year":"2017","journal-title":"Bone Marrow Transplant"},{"key":"bib5-20250621","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1182\/blood-2005-01-0272","article-title":"[18F]fluoro-2-deoxy-d-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome","volume":"106","year":"2005","journal-title":"Blood"},{"key":"bib6-20250621","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1007\/s00259-013-2435-6","article-title":"An international confirmatory study of the prognostic value of early PET\/CT in diffuse large B-cell lymphoma: comparison between Deauville criteria and \u0394SUVmax","volume":"40","year":"2013","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib7-20250621","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1093\/annonc\/mdn671","article-title":"Response assessment after an inductive CHOP or CHOP-like regimen with or without rituximab in 103 patients with diffuse large B-cell lymphoma: integrating 18fluorodeoxyglucose positron emission tomography to the International Workshop Criteria","volume":"20","year":"2009","journal-title":"Ann Oncol"},{"key":"bib8-20250621","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.2967\/jnumed.107.042093","article-title":"Early 18F-FDG PET for prediction of prognosis in patients with diffuse large B-cell lymphoma: SUV-based assessment versus visual analysis","volume":"48","year":"2007","journal-title":"J Nucl Med"},{"issue":"suppl 1","key":"bib9-20250621","doi-asserted-by":"crossref","first-page":"21S","DOI":"10.2967\/jnumed.108.057190","article-title":"PET\/CT for therapy response assessment in lymphoma","volume":"50","year":"2009","journal-title":"J Nucl Med"},{"key":"bib10-20250621","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1200\/JCO.2006.08.2305","article-title":"Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in lymphoma","volume":"25","year":"2007","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"bib11-20250621","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1002\/cncr.27855","article-title":"Total lesion glycolysis in positron emission tomography is a better predictor of outcome than the international prognostic index for patients with diffuse large B cell lymphoma","volume":"119","year":"2013","journal-title":"Cancer"},{"key":"bib12-20250621","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1182\/blood-2014-12-616474","article-title":"Utility of baseline 18FDG-PET\/CT functional parameters in defining prognosis of primary mediastinal (thymic) large B-cell lymphoma","volume":"126","year":"2015","journal-title":"Blood"},{"key":"bib13-20250621","doi-asserted-by":"crossref","first-page":"3801","DOI":"10.1158\/1078-0432.CCR-15-2825","article-title":"Molecular profile and FDG-PET\/CT total metabolic tumor volume improve risk classification at diagnosis for patients with diffuse large B-cell lymphoma","volume":"22","year":"2016","journal-title":"Clin Cancer Res"},{"key":"bib14-20250621","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1007\/s00259-016-3315-7","article-title":"Combination of baseline metabolic tumour volume and early response on PET\/CT improves progression-free survival prediction in DLBCL","volume":"43","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib15-20250621","doi-asserted-by":"crossref","first-page":"83544","DOI":"10.18632\/oncotarget.13180","article-title":"Prognostic value of total lesion glycolysis of baseline 18F-fluorodeoxyglucose positron emission tomography\/computed tomography in diffuse large B-cell lymphoma","volume":"7","year":"2016","journal-title":"Oncotarget"},{"key":"bib16-20250621","doi-asserted-by":"crossref","first-page":"276","DOI":"10.2967\/jnumed.116.180406","article-title":"Baseline total metabolic tumor volume measured with fixed or different adaptive thresholding methods equally predicts outcome in peripheral T cell lymphoma","volume":"58","year":"2017","journal-title":"J Nucl Med"},{"key":"bib17-20250621","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1053\/j.semnuclmed.2017.09.005","article-title":"Metabolic tumor volume metrics in lymphoma","volume":"48","year":"2018","journal-title":"Semin Nucl Med"},{"key":"bib18-20250621","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1007\/s00259-017-3907-x","article-title":"Combination of baseline FDG PET\/CT total metabolic tumour volume and gene expression profile have a robust predictive value in patients with diffuse large B-cell lymphoma","volume":"45","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib19-20250621","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial","volume":"20","year":"2019","journal-title":"Lancet Oncol"},{"key":"bib20-20250621","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","year":"2017","journal-title":"N Engl J Med"},{"key":"bib21-20250621","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","year":"2019","journal-title":"N Engl J Med"},{"key":"bib22-20250621","first-page":"1586","article-title":"Tisagenlecleucel in diffuse large B-cell lymphoma. reply","volume":"380","year":"2019","journal-title":"N Engl J Med"},{"key":"bib23-20250621","doi-asserted-by":"crossref","first-page":"7562","DOI":"10.1200\/JCO.2019.37.15_suppl.7562","article-title":"Association of high baseline metabolic tumor volume with response following axicabtagene ciloleucel in refractory large B-cell lymphoma","volume":"37","year":"2019","journal-title":"J Clin Oncol"},{"key":"bib24-20250621","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1200\/JCO.19.02103","article-title":"Axicabtagene ciloleucel in the non-trial setting: outcomes and correlates of response, resistance, and toxicity","volume":"38","year":"2020","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"bib25-20250621","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1182\/blood-2017-02-766691","article-title":"FDG-PET-driven consolidation strategy in diffuse large B-cell lymphoma: final results of a randomized phase 2 study","volume":"130","year":"2017","journal-title":"Blood"},{"key":"bib26-20250621","doi-asserted-by":"crossref","first-page":"e0210224","DOI":"10.1371\/journal.pone.0210224","article-title":"Prognostic value of baseline metabolic tumor volume and total lesion glycolysis in patients with lymphoma: a meta-analysis","volume":"14","year":"2019","journal-title":"PLoS One"},{"key":"bib27-20250621","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1182\/blood.2019003526","article-title":"High total metabolic tumor volume at baseline predicts survival independent of response to therapy","volume":"135","year":"2020","journal-title":"Blood"},{"key":"bib28-20250621","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1002\/ajh.25951","article-title":"Commercial anti-CD19 CAR T cell therapy for patients with relapsed\/refractory aggressive B cell lymphoma in a European center","volume":"95","year":"2020","journal-title":"Am J Hematol"},{"key":"bib29-20250621","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1007\/s00259-014-2705-y","article-title":"Metabolic tumour volumes measured at staging in lymphoma: methodological evaluation on phantom experiments and patients","volume":"41","year":"2014","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib30-20250621","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1007\/s00259-014-2961-x","article-title":"FDG PET\/CT: EANM procedure guidelines for tumour imaging: version 2.0","volume":"42","year":"2015","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib31-20250621","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","year":"2014","journal-title":"J Clin Oncol"},{"key":"bib32-20250621","doi-asserted-by":"crossref","first-page":"3268","DOI":"10.1182\/bloodadvances.2020001900","article-title":"High metabolic tumor volume is associated with decreased efficacy of axicabtagene ciloleucel in large B-cell lymphoma","volume":"4","year":"2020","journal-title":"Blood Adv"},{"key":"bib33-20250621","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/j.bbmt.2019.02.008","article-title":"Role of Fluorodeoxyglucose positron emission tomography\/computed tomography in predicting the adverse effects of chimeric antigen receptor T cell therapy in patients with non-Hodgkin lymphoma","volume":"25","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"bib34-20250621","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1016\/j.bbmt.2019.08.015","article-title":"Use of chimeric antigen receptor T cell therapy in clinical practice for relapsed\/refractory aggressive B cell non-Hodgkin lymphoma: an expert panel opinion from the American Society for Transplantation and Cellular Therapy","volume":"25","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"bib35-20250621","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.1200\/JCO.19.02104","article-title":"Standard-of-care axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma: results from the US Lymphoma CAR T Consortium","volume":"38","year":"2020","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"bib37-20250621","doi-asserted-by":"crossref","first-page":"7558","DOI":"10.1200\/JCO.2019.37.15_suppl.7558","article-title":"Preliminary results of earlier steroid use with axicabtagene ciloleucel (axi-cel) in patients with relapsed\/refractory large B-cell lymphoma (R\/R LBCL)","volume":"37","year":"2019","journal-title":"J Clin Oncol"},{"key":"bib38-20250621","doi-asserted-by":"crossref","first-page":"5","DOI":"10.2217\/imt-2020-0188","article-title":"Pseudoprogression of extramedullary disease in relapsed acute lymphoblastic leukemia after CAR T-cell therapy","volume":"13","year":"2021","journal-title":"Immunotherapy"},{"key":"bib39-20250621","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1182\/blood-2016-05-718528","article-title":"Refinement of the Lugano classification lymphoma response criteria in the era of immunomodulatory therapy","volume":"128","year":"2016","journal-title":"Blood"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000003756","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T21:03:35Z","timestamp":1750539815000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000003756"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,11]]},"references-count":38,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000003756","relation":{},"ISSN":["1536-0229","0363-9762"],"issn-type":[{"value":"1536-0229","type":"electronic"},{"value":"0363-9762","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6,11]]}}}